{"schema_version":"secwatch.filing_event.v1","accession":"0001267602-24-000029","form_type":"8-K","ticker":null,"cik":"0001267602","company_name":"ALIMERA SCIENCES INC","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.657458+00:00","generated_at":"2026-06-02T00:21:04.520988+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alimera Q1 revenue up 70% to $23M; adjusted EBITDA positive; reaffirms FY guidance","bullets":["Net revenue $23.0M (+70% YoY); US $14.6M (+92%), International $8.5M (+42%).","Net loss $6.3M vs $5.0M loss in Q1 2023; adjusted EBITDA positive $1.8M vs ($2.4M) loss.","Global end user demand 4,028 units (+23% YoY). Reaffirms FY2024 revenue of $105M and ≥20% EBITDA margin.","Completed enrollment in Synchronicity Study (YUTIQ for uveitis); first patient randomized in DRCR Retina Network study for radiation retinopathy.","NICE recommends ILUVIEN for phakic DME patients in UK; increased term loan by $5M with SLR Capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001267602-24-000029","json":"https://secwatch.observer/filing/0001267602-24-000029.json","markdown":"https://secwatch.observer/filing/0001267602-24-000029.md","text":"https://secwatch.observer/filing/0001267602-24-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267602/000126760224000029/0001267602-24-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267602/000126760224000029/alim-20240514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:21:04.520988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9a428a7f59ab230f6de1fd4f8f86870ec7aec03","claim":"ALIMERA SCIENCES INC reported first quarter of 2024 results: revenue $23.0 million. Guidance reaffirmed.","evidence_excerpt":"such a filing. ‎ 2 --- EX-99.1 (EX-99.1) --- Exhibit 99.1     FOR IMMEDIATE RELEASE   Alimera Sciences Reports First Quarter 202 4 Results  · Net Revenue up 70 % to $ 23 Million vs. Q1 202 3 · Global End User Demand Up 2 3 % vs. Q1 202 3 · Re iterates I mproved 2024 Net Revenue and Adjusted EBITDA G uidance  ATLANTA , May 14 , 202 4 -- Alimera Sciences,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267602/000126760224000029/0001267602-24-000029-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Revenue","value":"$23.0 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}